Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 1.00 |
| ▸ | CCR5 | P51681 | 12/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3079829 | 1.00 | KCNH2 (1.00) | KCNH2CCR5 | |
| SCHEMBL5148952 | 0.94 | KCNH2 (1.00) | KCNH2CCR5 | |
| SCHEMBL5148957 | 0.94 | KCNH2 (1.00) | KCNH2CCR5 | |
| SCHEMBL3070606 | 0.94 | KCNH2 (1.00) | KCNH2CCR5 | |
| SCHEMBL3070604 | 0.94 | KCNH2 (1.00) | KCNH2CCR5 | |
| SCHEMBL13178981 | 0.93 | KCNH2 (0.90) | KCNH2CCR5 | |
| SCHEMBL3073059 | 0.93 | KCNH2 (0.88) | KCNH2CCR5 | |
| SCHEMBL3073056 | 0.93 | KCNH2 (0.88) | KCNH2CCR5 | |
| SCHEMBL2575126 | 0.93 | KCNH2 (0.90) | KCNH2CCR5 | |
| SCHEMBL2575130 | 0.93 | KCNH2 (0.90) | KCNH2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790740-B2 | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation | PFIZER INC (US) | 2010-09-07 | — | — | US | claimed |
| US-20080045563-A1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | PFIZER INC. | 2008-02-21 | — | — | US | claimed |
| US-7309790-B2 | Chemical compounds | PFIZER INC (US) | 2007-12-18 | — | — | US | claimed |
| EP-1682545-B1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | PFIZER LTD (GB) | 2007-12-12 | — | — | EP | claimed |
| US-20050131011-A1 | Chemical compounds | PFIZER, INC. | 2005-06-16 | — | — | US | claimed |
| US-7790740-B2 | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation | PFIZER INC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790740-B2 | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation | PFIZER INC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790740-B2 | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation | PFIZER INC (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080045563-A1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045563-A1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045563-A1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| US-7309790-B2 | Chemical compounds | PFIZER INC (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309790-B2 | Chemical compounds | PFIZER INC (US) | 2007-12-18 | — | — | US | disclosed |
| EP-1682545-B1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | PFIZER LTD (GB) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045563-A1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | CCR5, CCR2, CX3CR1 | KCNH2 2405/4885CCR5 1/4885 |
| US-20050131011-A1 | Chemical compounds | CCR5, CCR2, CX3CR1 | KCNH2 3565/4885CCR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.